Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis

Back to Search
Print
Bookmark Trial

NCT00962741

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Westmead, Sydney, New South Wales, 2145, Australia
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Juvenile Idiopathic Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
2-17 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male and female subjects with a diagnosis per International League of Associations for Rheumatology (ILAR) criteria of extended oligoarticular juvenile idiopathic arthritis (JIA) between the ages of 2 and 17 years; enthesitis-related arthritis (ERA) between the ages of 12 and 17 years; or psoriatic arthritis (PsA) between the ages of 12 and 17 years.

- >= 2 active joints and the following for the relevant JIA subtype: extended oligoarticular JIA or PsA with a history of intolerance or an unsatisfactory response to a disease modifying antirheumatic drug (DMARD); or ERA with a history of intolerance or an unsatisfactory response to a nonsteroidal anti-inflammatory drug (NSAID) or a DMARD.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Systemic JIA, persistent oligoarticular JIA, polyarticular JIA, or undifferentiated
arthritis per ILAR criteria.


- Other rheumatic diseases.


- Active uveitis within 6 months of the baseline visit.


- Any other significant health problem.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Juvenile Idiopathic ArthritisEnbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]
NCT01145352
  1. Tokyo,
ALL GENDERS
5 Years+
years
MULTIPLE SITES
Juvenile Idiopathic ArthritisPharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)
NCT01513902
  1. Minneapolis, Minnesota
  2. Minneapolis, Minnesota
  3. Cincinnati, Ohio
  4. Portland, Oregon
  5. Bad Bramstedt,
  6. Hamburg,
  7. St. Augustin,
  8. Krakow,
  9. Lodz,
  10. Piestany,
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Juvenile Idiopathic ArthritisStudy Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
NCT00962741
  1. Westmead, Sydney, New South Wales
  2. Parkville, Melbourne, Victoria
  3. Brussels,
  4. Gent,
  5. Leuven,
  6. Barranquilla, Atlantico
  7. Bogota, Cundinamarca
  8. Bucaramanga, Santander
  9. Brno,
  10. Praha 2,
  11. Praha 2,
  12. Le Kremlin Bicetre,
  13. Paris Cedex 14,
  14. Paris,
  15. Berlin,
  16. Bremen,
  17. Hamburg,
  18. Hannover,
  19. St. Augustin,
  20. Budapest,
  21. Chieti,
  22. Riga,
  23. Riga,
  24. Vilnius,
  25. Mexico City,
  26. Utrecht,
  27. Oslo,
  28. Bydgoszcz,
  29. Krakow,
  30. Warszawa,
  31. Wroclaw,
  32. Moscow,
  33. Saint-Petersburg,
  34. Belgrade,
  35. Nis,
  36. Kosice,
  37. Piestany,
  38. Ljubljana,
  39. Esplugues de Llobregat, Barcelona
  40. Madrid,
  41. Madrid,
  42. Valencia,
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Juvenile Idiopathic ArthritisEfficacy Study Of Tofacitinib In Pediatric JIA Population
NCT02592434
  1. Little Rock, Arkansas
  2. Little Rock, Arkansas
  3. Loma Linda, California
  4. Loma Linda, California
  5. Loma Linda, California
  6. Loma Linda, California
  7. Loma Linda, California
  8. Los Angeles, California
  9. San Bernardino, California
  10. San Diego, California
  11. San Diego, California
  12. San Diego, California
  13. San Diego, California
  14. Hartford, Connecticut
  15. Hartford, Connecticut
  16. Washington, District of Columbia
  17. Washington, District of Columbia
  18. Miami, Florida
  19. Atlanta, Georgia
  20. Atlanta, Georgia
  21. Atlanta, Georgia
  22. Augusta, Georgia
  23. Chicago, Illinois
  24. Chicago, Illinois
  25. Chicago, Illinois
  26. Indianapolis, Indiana
  27. Indianapolis, Indiana
  28. Boston, Massachusetts
  29. Minneapolis, Minnesota
  30. Minneapolis, Minnesota
  31. Hackensack, New Jersey
  32. Bronx, New York
  33. Bronx, New York
  34. Lake Success, New York
  35. New Hyde Park, New York
  36. New York, New York
  37. New York, New York
  38. Charlotte, North Carolina
  39. Charlotte, North Carolina
  40. Charlotte, North Carolina
  41. Cincinnati, Ohio
  42. Portland, Oregon
  43. Portland, Oregon
  44. Philadelphia, Pennsylvania
  45. Austin, Texas
  46. Austin, Texas
  47. Houston, Texas
  48. Houston, Texas
  49. Houston, Texas
  50. Houston, Texas
  51. Houston, Texas
  52. Salt Lake City, Utah
  53. Salt Lake City, Utah
  54. Seattle, Washington
  55. Westmead, New South Wales
  56. Parkville, Victoria
  57. Birmingham, WEST Midlands
  58. Bristol,
  59. Bristol,
  60. Madrid,
  61. Tolyatti,
  62. Saint-Petersburg,
  63. San Luis Potosi,
  64. Istanbul,
  65. Curitiba, Parana
  66. Moscow,
  67. Vancouver, British Columbia
  68. Vinnitsya,
  69. Calgary, Alberta
  70. Istanbul,
  71. Juiz de Fora, MG
  72. Haifa,
  73. San Luis Potosi,
  74. San Miguel de Tucuman, Tucuman
  75. Sao Paulo,
  76. Moscow,
  77. Montreal, Quebec
  78. Vancouver, British Columbia
  79. Kayseri,
  80. Ankara,
  81. Caba,
  82. Calgary, Alberta
  83. Bydgoszcz,
  84. San Luis Potosi,
  85. Kfar Saba,
  86. Rosario, Santa FE
  87. Istanbul,
  88. Guadalajara, Jalisco
  89. Valencia,
  90. Ivano-Frankivsk,
  91. Leuven,
  92. Salvador, Bahia
  93. Ramat Gan,
  94. Sao Paulo, SAN Paulo
  95. Moscow,
  96. San Luis Potosi,
  97. Montreal, Quebec
  98. Curitiba, Parana
  99. Botucatu, SAO Paulo
  100. Minneapolis, Minnesota
  101. Rio de Janeiro, RJ
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
Official Title  ICMJE A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-Term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis
Brief Summary This study will evaluate the effect of etanercept on the clinical benefit, safety, and physical functioning (ability to function in daily life) in children and adolescent subjects with 3 subtypes of childhood arthritis.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Arthritis, Juvenile Idiopathic
Intervention  ICMJE Drug: Etanercept
Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
Other Name: Enbrel
Study Arms  ICMJE Experimental: 1
Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
Intervention: Drug: Etanercept
Publications * Foeldvari I, Constantin T, Vojinovi? J, Horneff G, Chasnyk V, Dehoorne J, Panaviene V, Su?i? G, Stanevicha V, Kobusinska K, Zuber Z, Dobrzyniecka B, Nikishina I, Bader-Meunier B, Breda L, Dole?alová P, Job-Deslandre C, Rumba-Rozenfelde I, Wulffraat N, Pedersen RD, Bukowski JF, Vlahos B, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Arthritis Res Ther. 2019 May 23;21(1):125. doi: 10.1186/s13075-019-1916-9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 5, 2012)		127
Original Estimated Enrollment  ICMJE
 (submitted: August 19, 2009)		100
Actual Study Completion Date  ICMJE January 2013
Actual Primary Completion Date June 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male and female subjects with a diagnosis per International League of Associations for Rheumatology (ILAR) criteria of extended oligoarticular juvenile idiopathic arthritis (JIA) between the ages of 2 and 17 years; enthesitis-related arthritis (ERA) between the ages of 12 and 17 years; or psoriatic arthritis (PsA) between the ages of 12 and 17 years.
  • >= 2 active joints and the following for the relevant JIA subtype: extended oligoarticular JIA or PsA with a history of intolerance or an unsatisfactory response to a disease modifying antirheumatic drug (DMARD); or ERA with a history of intolerance or an unsatisfactory response to a nonsteroidal anti-inflammatory drug (NSAID) or a DMARD.

Exclusion Criteria:

  • Systemic JIA, persistent oligoarticular JIA, polyarticular JIA, or undifferentiated arthritis per ILAR criteria.
  • Other rheumatic diseases.
  • Active uveitis within 6 months of the baseline visit.
  • Any other significant health problem.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 2 Years to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Belgium,   Colombia,   Czech Republic,   France,   Germany,   Hungary,   Italy,   Latvia,   Lithuania,   Mexico,   Netherlands,   Norway,   Poland,   Russian Federation,   Serbia,   Slovakia,   Slovenia,   Spain
Removed Location Countries Argentina,   Brazil,   Denmark,   Greece,   Sweden,   Taiwan
 
Administrative Information
NCT Number  ICMJE NCT00962741
Other Study ID Numbers  ICMJE 0881A1-3338
B1801014
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP